Pauline Du Rusquec

Paris, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 31 publications

Efficacy and safety of second-line treatments in patients with advanced EGFR-mutated non-small cell lung cancer progressing on osimertinib without identified targetable resistance mechanism at progression.

Efficacy and safety of second-line treatments in patients with advanced EGFR-mutated non-small cell lung cancer progressing on osimertinib without identified targetable resistance mechanism at progression.

Journal: Respiratory medicine and research

Published: October 12, 2025

Upper-gastrointestinal tract toxicities associated with Immune Checkpoint Inhibitors (ICI)

Upper-gastrointestinal tract toxicities associated with Immune Checkpoint Inhibitors (ICI)

Journal: Bulletin du cancer

Published: July 01, 2025

Benchmarking progression-free survival ratio as primary endpoint in precision oncology clinical trials.

Benchmarking progression-free survival ratio as primary endpoint in precision oncology clinical trials.

Journal: NPJ precision oncology

Published: May 14, 2025

Upfront osimertinib and as sequential therapy in patients with EGFR-mutant non-small cell lung cancer (NSCLC): benefit across patients groups in a real-world retrospective cohort-the smile study.

Upfront osimertinib and as sequential therapy in patients with EGFR-mutant non-small cell lung cancer (NSCLC): benefit across patients groups in a real-world retrospective cohort-the smile study.

Journal: Translational lung cancer research

Published: September 23, 2024

Influence of smoking on the efficacy of immunotherapy in advanced lung cancers

Influence of smoking on the efficacy of immunotherapy in advanced lung cancers

Journal: Revue des maladies respiratoires

Published: September 01, 2024

Real-World Survival Impact of New Treatment Strategies for Lung Cancer: A 2000-2020 French Cohort.

Real-World Survival Impact of New Treatment Strategies for Lung Cancer: A 2000-2020 French Cohort.

Journal: Cancers

Published: June 15, 2024

COMPOSIT study: evaluating osimertinib combination with targeted therapies in EGFR-mutated non-small cell lung cancer.

COMPOSIT study: evaluating osimertinib combination with targeted therapies in EGFR-mutated non-small cell lung cancer.

Journal: The oncologist

Published: April 01, 2024

Capmatinib efficacy for METex14 non-small cell lung cancer patients: Results of the IFCT-2104 CAPMATU study.

Capmatinib efficacy for METex14 non-small cell lung cancer patients: Results of the IFCT-2104 CAPMATU study.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: March 30, 2024

Outcomes Analysis of Patients Receiving Local Ablative Therapy for Oligoprogressive Metastatic NSCLC Under First-Line Immunotherapy.

Outcomes Analysis of Patients Receiving Local Ablative Therapy for Oligoprogressive Metastatic NSCLC Under First-Line Immunotherapy.

Journal: Clinical lung cancer

Published: March 04, 2024

Clinical characteristic and survival outcomes of patients with advanced NSCLC according to KRAS mutational status in the French real-life ESME cohort.

Clinical characteristic and survival outcomes of patients with advanced NSCLC according to KRAS mutational status in the French real-life ESME cohort.

Journal: ESMO open

Published: February 10, 2024

Palliative care integration and end-of-life care intensity for patients with NSCLC.

Palliative care integration and end-of-life care intensity for patients with NSCLC.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: December 20, 2023

Outcome of adrenocortical carcinoma patients included in early phase clinical trials: Results from the French network ENDOCAN-COMETE.

Outcome of adrenocortical carcinoma patients included in early phase clinical trials: Results from the French network ENDOCAN-COMETE.

Journal: European journal of cancer (Oxford, England : 1990)

Published: March 30, 2023

Showing 1-12 of 31

Last Updated: 09/26/2026